Nurix Therapeutics (NRIX) Payables (2019 - 2025)
Historic Payables for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $11.2 million.
- Nurix Therapeutics' Payables fell 232.54% to $11.2 million in Q4 2025 from the same period last year, while for Nov 2025 it was $11.2 million, marking a year-over-year decrease of 232.54%. This contributed to the annual value of $11.2 million for FY2025, which is 232.54% down from last year.
- Per Nurix Therapeutics' latest filing, its Payables stood at $11.2 million for Q4 2025, which was down 232.54% from $8.6 million recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Payables ranged from a high of $11.5 million in Q4 2024 and a low of $2.2 million during Q3 2023
- For the 5-year period, Nurix Therapeutics' Payables averaged around $6.0 million, with its median value being $5.9 million (2024).
- In the last 5 years, Nurix Therapeutics' Payables crashed by 6386.92% in 2023 and then skyrocketed by 11972.95% in 2025.
- Over the past 5 years, Nurix Therapeutics' Payables (Quarter) stood at $6.6 million in 2021, then fell by 23.85% to $5.1 million in 2022, then increased by 26.4% to $6.4 million in 2023, then soared by 79.38% to $11.5 million in 2024, then dropped by 2.33% to $11.2 million in 2025.
- Its Payables stands at $11.2 million for Q4 2025, versus $8.6 million for Q3 2025 and $6.0 million for Q2 2025.